肿瘤坏死因子-α抑制药致药源性抗体的研究现状

Status of research on drug induced antibodies following treatment with tumor necrosis factor-α inhibitors

肿瘤坏死因子(TNF)-α抑制药(TNFi)作为生物靶向制剂,临床上主要用于治疗类风湿关节炎(RA)、克罗恩病(CD)、溃疡性结肠炎(UC)、强直性脊柱炎(AS)、银屑病(Ps O)等炎症性疾病。然而,所有生物制剂治疗期间可诱导药源性抗体的产生,包括抗药物抗体(ADAbs)与自身抗体。本文针对TNFi致药源性抗体的发生发展及其安全性做一简要综述,以期为TNFi的临床治疗提供一定的参考依据。

Tumor necrosis factor -a inhibitors （TNFi） are targeted bio- logic agents used in the management of inflammatory disorders, such as rheumatoid arthritis （RA）, erohn disease （CD）, ulcerative colitis （UC）, ankylosing spondylitis （ AS ）, psoriasis （ PsO ） and other inflammatory diseases. However, all biological agents are immunogenic, resulting in the formation of anti - drug antibodies （ADAbs） and autoantibodies. This paper reviews the development of drug induced antibodies and the safety of therapy following treatment with TNFi so as to provide references for clinical treatment.